INTRODUCTION AND OBJECTIVES: The combination of the human immunodeficiency virus (HIV) protease inhibitors lopinavir and ritonavir has been a standard regimen used to treat HIV infection. Ritonavir acts as a chemical booster to enhance lopinavir's activity. Lopinavir has recently been shown to act against cancer by inducing endoplasmic reticulum (ER) stress, and we thought that the combination would kill renal cancer cells by inducing robust ER stress.
METHODS: The viability and clonogenicity of renal cancer cells (769-P, 786-O, Caki-2) treated with clinically feasible concentrations of lopinavir (10-40 mM) and/or ritonavir (5-10 mM) were assessed by MTS assay and colony formation assay. Apoptosis was evaluated by annexin-V assay. Cell cycle analysis was done using flow cytometry. Induction of ER stress and the expression of cell-cycle regulators, apoptosis-associated proteins, NOXA, Akt, BCL-2, and survivin were evaluated by western blot analysis. Drug synergism was assessed by the Chou-Talalay method.
RESULTS: Lopinavir in combination with ritonavir inhibited renal cancer growth synergistically (combination index <1). The combination also inhibited clonogenic survival of cancer cells significantly (p <0.05). It perturbed the cell cycle by inhibiting the expression of cyclin D1 and cyclin-dependent kinase 4, increasing the cells in the sub-G1 fraction. The combination caused apoptosis synergistically: 10-20 mM lopinavir increased the number of annexin-V positive cells and the expression of cleaved poly(ADP-ribose) polymerase slightly but in combination with 10 mM ritonavir increased both drastically. As expected, the combination induced ER stress evidenced by the increased expression of the ER stress markers glucose-regulated protein 78 and endoplasmic reticulum resident protein 44. Furthermore, increased expression of NOXA confirmed that the combination-induced apoptosis was a result of ER stress. We also found that the combination decreased the expression of the antiapoptotic proteins BCL-2 and survivin by inhibiting the Akt signaling pathway.
CONCLUSIONS: The combination of lopinavir and ritonavir induces ER stress and causes renal cancer apoptosis synergistically. Inhibition of the Akt pathway is another important mechanism of its action.
Source of Funding: none

MP73-13 PHENOXODIOL, A NOVEL SOY ISOFLAVONE ANALOG, INHIBITS AKT PATHWAY AND INDUCES RENAL CANCER APOPTOSIS
Makoto Isono*, Akinori Sato, Takako Asano, Kazuki Okubo, Tomohiko Asano, Tokorozawa, Japan INTRODUCTION AND OBJECTIVES: There are no curative agents for advanced renal cancer, and a novel treatment approach is urgently needed. Soy isoflavones are dietary nutrients that have been shown to inhibit cancer development and progression, and phenoxodiol is a novel isoflavone analog being tested in clinical trials. Because its efficacy in renal cancer is unknown, in the present study we investigated its antineoplastic activity and mechanism of action in renal cancer cells.
METHODS: A panel of renal cancer cells (769-P, 786-O, Caki-2) was treated with phenoxodiol (5-20 mM). The cell viability and clonogenicity were assessed by MTS assay and colony formation assay. Cell cycle analysis was done using flow cytometry. Apoptosis and necrosis were detected by flow cytometry after staining the cells with annexin V and 7-amino-actinomycin D (7-AAD). The expression of cyclin D1, cyclin-dependent kinase (CDK) 4, cleaved poly(ADP-ribose) polymerase (PARP), FLICE inhibitory protein (FLIP), and Akt was evaluated by western blotting.
RESULTS: MTS assay results showed that phenoxodiol decreased renal cancer viability in a time-and dose-dependent manner (IC50: 19.9-28.8 mM). It also inhibited colony formation significantly (p <0.05) and perturbed the cell cycle: 24-hour treatment with 20 mM phenoxodiol induced marked G1-S arrest but prolonged treatment (48-72 hours) increased the number of cells in the sub-G1 fraction, suggesting that phenoxodiol disrupted cell cycle checkpoints. These changes were associated with decreased expression of the cell-cycle regulators cyclin D1 and CDK4. Treatment with phenoxodiol increased the numbers of 7-AAD-positive cells as well as annexin-V positive cells and increased the expression of cleaved PARP, demonstrating that the phenoxodiol-induced apoptosis was late apoptosis. Phenoxodiol also inhibited the Akt pathway by causing dephosphorylation of Akt. This inhibition of the Akt pathway inhibited expression of the apoptosis inhibitor FLIP and thus led to renal cancer apoptosis.
CONCLUSIONS: Phenoxodiol induces apoptosis of renal cancer cells by inhibiting the Akt pathway.
Source of Funding: none
MP73-14 CAPABILITY OF ELECTRICAL IMPEDANCE SPECTROSCOPY SENSOR ON A NEEDLE AS A NOVEL TOOL TO ESTIMATE MALIGNANT RENAL TUMOR MARGIN: EX-VIVO DEMARCATION OF TUMOR AND SURGICAL MARGIN
INTRODUCTION AND OBJECTIVES: To estimate tumor margin during partial nephrectomy, we developed a needle having electrochemical impedance spectroscopy (EIS) sensor on the tip of a needle which we named 00 EoN (EIS-on-a needle) 00 . In this study, the impedances of renal parenchyma in accordance with the distance from the tumor were measured by using EoN to evaluate the capability of the device in detecting the tumor margin.
METHODS: Microelectromechanical-system technology was applied to fabricate EoN, which is a 22-gauge needle with interdigitated electrodes on its tip. For the experiment, 10 renal specimen consisted of tumor and its surgical margin resected by partial nephrectomy were used. EoN was inserted into the surgical margin of the specimens and the impedance was measured while the device was accessing toward the tumor at the frequency range from 0.1 kHz to 1 MHz. The areas within the specimens where the impedance was measured were categorized into five sections according to the distance from the tumor: 1) surgical margin at > 6 mm and 8 mm from the tumor as section I; 2) between > 4 mm and 6 mm as section II; 3) between > 2 mm and 4 mm as section III; 4) between > 0 mm and 2 mm as section IV; and 5) within the tumor as section V. The magnitude and phase angle of impedance between each sections were compared by using repeated-measures analysis of variance at each single frequency.
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